The impact of buprenorphine on treatment of opioid dependence in a Medicaid population: Recent service utilization trends in the use of buprenorphine and methadone

Drug and Alcohol Dependence

Volumn 123, Issue 1-3, 2012, Pages 72-78

  Stein, Bradley D ^a,c   Gordon, Adam J ^b   Sorbero, Mark ^a   Dick, Andrew W ^c   Schuster, James ^a   Farmer, Carrie ^c  

^a and Outcomes   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c RAND CORPORATION   (United States)

Author keywords

Buprenorphine; Methadone; Office based treatment; Opiate dependence

Indexed keywords

BUPRENORPHINE; METHADONE;

ADULT; ARTICLE; CLINICAL EVALUATION; COMORBIDITY; DISEASE SEVERITY; DRUG EFFECT; DRUG USE; FEMALE; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; OPIATE ADDICTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RURAL AREA; TREND STUDY;

ADOLESCENT; ADULT; AGE FACTORS; BUPRENORPHINE; DRUG UTILIZATION; ETHNIC GROUPS; FEMALE; HUMANS; MALE; MEDICAID; METHADONE; MID-ATLANTIC REGION; MIDDLE AGED; NARCOTIC ANTAGONISTS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; RURAL POPULATION; SEX FACTORS; SOCIOECONOMIC FACTORS; UNITED STATES; URBAN POPULATION; YOUNG ADULT;

EID: 84861220851     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2011.10.016     Document Type: Article

References (41)

1. Alegria M., Canino G., Rios R., Vera M., Calderon J., Rusch D., Ortega A.N. Mental health care for Latinos: Inequalities in use of specialty mental health services among Latinos, African Americans, and non-Latino Whites. Psychiatr. Serv. 2002, 53:1547-1555.
2. American Methadone Treatment Association Methadone Maintenance Program and Patient Census in the US 1998, American Methadone Treatment Association, New York.
3. Arfken C.L., Johanson C.E., di Menza S., Schuster C.R. Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: national surveys of physicians. J. Subst. Abuse Treat. 2010, 39:96-104.
4. Barnett P.G. Comparison of costs and utilization among buprenorphine and methadone patients. Addiction 2009, 104:982-992.
5. Baxter J.D., Clark R.E., Samnaliev M., Leung G.Y., Hashemi L. Factors associated with Medicaid patients' access to buprenorphine treatment. J. Subst. Abuse Treat. 2011, 41:88-96.
6. Becker W.C., Fiellin D.A., Merrill J.O., Schulman B., Finkelstein R., Olsen Y., Busch S.H. Opioid use disorder in the United States: insurance status and treatment access. Drug Alcohol Depend. 2008, 94:207-213.
7. Cicero T.J., Surratt H., Inciardi J.A., Munoz A. Relationship between therapeutic use and abuse of opioid analgesics in rural, suburban, and urban locations in the United States. Pharmacoepidemiol. Drug Saf. 2007, 16:827-840.
8. Clark R.E., Samnaliev M., Baxter J.D., Leung G.Y. The evidence doesn't justify steps by state Medicaid programs to restrict opioid addiction treatment with buprenorphine. Health Aff. (Millwood) 2011, 30:1425-1433.
9. Cooper L.A., Gonzales J.J., Gallo J.J., Rost K.M., Meredith L.S., Rubenstein L.V., Wang N.Y., Ford D.E. The acceptability of treatment for depression among African-American, Hispanic, and white primary care patients. Med. Care 2003, 41:479-489.
10. Daley M.C. Race, managed care, and the quality of substance abuse treatment. Adm. Policy Ment. Health 2005, 32:457-476.
11. Ducharme L., Abraham A. State policy influence on the early diffusion of buprenorphine in community treatment programs. Subst. Abuse Treat. Prev. Policy 2008, 3:17-27.
12. Gfroerer J.C., Larson S.L., Colliver J.D. Drug use patterns and trends in rural communities. J. Rural Health 2007, 23:10-15.
13. Gordon A.J., Fiellin D.A., Friedmann P.D., Gourevitch M.N., Kraemer K.L., Arnsten J.H., Saitz R. Update in addiction medicine for the primary care clinician. J. Gen. Intern. Med. 2008, 23:2112-2116.
14. Gordon A.J., Trafton J.A., Saxon A.J., Gifford A.L., Goodman F., Calabrese V.S., McNicholas L., Liberto J. Implementation of buprenorphine in the Veterans Health Administration: results of the first 3 years. Drug Alcohol Depend. 2007, 90:292-296.
15. Harris A.H., Gospodarevskaya E., Ritter A.J. A randomised trial of the cost effectiveness of buprenorphine as an alternative to methadone maintenance treatment for heroin dependence in a primary care setting. Pharmacoeconomics 2005, 23:77-91.
16. Jones E.S., Moore B.A., Sindelar J.L., O'Connor P.G., Schottenfeld R.S., Fiellin D.A. Cost analysis of clinic and office-based treatment of opioid dependence: results with methadone and buprenorphine in clinically stable patients. Drug Alcohol Depend. 2009, 99:132-140.
17. Knudsen H.K., Ducharme L.J., Roman P.M. Early buprenorphine adoption in substance abuse treatment centers: data from the public and private sectors. J. Subst. Abuse Treat. 2006, 30:363-373.
18. Knudsen H.K., Ducharme L.J., Roman P.M. The adoption of medications in substance abuse treatment: associations with organizational characteristics and technology clusters. Drug Alcohol Depend. 2007, 87:164-174.
19. Koch A.L., Arfken C.L., Schuster C.R. Characteristics of US substance abuse treatment facilities adopting buprenorphine in its initial stage of availability. Drug Alcohol Depend. 2006, 83:274-278.
20. Krantz M.J., Mehler P.S. Treating opioid dependence. Growing implications for primary care. Arch. Intern. Med. 2004, 164:277-288.
21. Leslie L.K., Weckerly J., Landsverk J., Hough R.L., Hurlburt M.S., Wood P.A. Racial/ethnic differences in the use of psychotropic medication in high-risk children and adolescents. J. Am. Acad. Child Adolesc. Psychiatry 2003, 42:1433-1442.
22. Ling W., Jacobs P., Hillhouse M., Hasson A., Thomas C., Freese T., Sparenborg S., McCarty D., Weiss R., Saxon A., Cohen A., Straus M., Brigham G., Liu D., McLaughlin P., Tai B. From research to the real world: buprenorphine in the decade of the Clinical Trials Network. J. Subst. Abuse Treat. 2010, 38:S53-S60.
23. Lurie N., Popkin M., Dysken M., Moscovice I., Finch M. Accuracy of diagnoses of schizophrenia in Medicaid claims. Hosp. Community Psych. 1992, 43:69-71.
24. Marsch L.A. The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta-analysis. Addiction 1998, 93:515-532.
25. Mattick R.P., Ali R., White J.M., O'Brien S., Wolk S., Danz C. Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. Addiction 2003, 98:441-452.
26. Mattick R.P., Breen C., Kimber J., Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst. Rev. 2009, CD002209.
27. Mattick R.P., Kimber J., Breen C., Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst. Rev. 2008, CD002207.
28. Moos R.H., Moos B.S., Finney J.W. Predictors of deterioration among patients with substance-use disorders. J. Clin. Psychol. 2001, 57:1403-1419.
29. National Consensus Development Panel Effective medical treatment of opiate addiction. JAMA 1998, 280:1936-1943.
30. National Institute of Drug Abuse, 2006. Principles of Effective Treatment for Criminal Justice Populations. Rockville, MD.
31. National Institute of Drug Abuse National Quality Forum Evidence-based Treatment Practices for Substance Use Disorders: Workshop Proceedings 2005.
32. O'Connor P.G., Oliveto A.H., Shi J.M., Triffleman E.G., Carroll K.M., Kosten T.R., Rounsaville B.J., Pakes J.A., Schottenfeld R.S. A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic. Am. J. Med. 1998, 105:100-105.
33. Sullivan L.E., Chawarski M., O'Connor P.G., Schottenfeld R.S., Fiellin D.A. The practice of office-based buprenorphine treatment of opioid dependence: is it associated with new patients entering into treatment?. Drug Alcohol Depend. 2005, 79:113-116.
34. U.S.Department of Health Human Services Results from the 2009 National Survey on Drug Use and Health: Vol. 1. Summary of National Findings 2010, Substance Abuse and Mental Health Services Administration, Rockville, MD.
35. U.S.Department of Justice Buprenorphine: Potential for Abuse. Intellegence Bulletin 2004, National Drug Intellegence Center, Johnstown, PA, pp. 1-8.
36. Volkow, N.D., 2004. NIDA at 30: committed to scientific solutions for drug addiction problems. NIDA Notes, 19. Accessed on January 15 2007. http://www.drugabuse.gov/NIDA_notes/NNvol19N1/DirRep.
37. Wang P.S., Demler O., Kessler R.C. Adequacy of treatment for serious mental illness in the United States. Am. J. Public Health 2002, 92:92-98.
38. Wells K., Klap R., Koike A., Sherbourne C. Ethnic disparities in unmet need for alcoholism, drug abuse, and mental health care. Am. J. Psychiatry 2001, 158:2027-2032.
39. Wu L.T. Gender and racial/ethnic differences in addiction severity, HIV risk, and quality of life among adults in opioid detoxification: results from the National Drug Abuse Treatment Clinical Trials Network. Subst. Abuse Rehabil. 2010, 13-22.
40. Young A.S., Klap R., Sherbourne C.D., Wells K.B. The quality of care for depressive and anxiety disorders in the United States. Arch. Gen. Psychiatry 2001, 58:55-61.
41. Zito J.M., Safer D.J., Zuckerman I.H., Gardner J.F., Soeken K. Effect of Medicaid eligibility category on racial disparities in the use of psychotropic medications among youths. Psychiatr. Serv. 2005, 56:157-163.